COLUMBIA (US) — Leptin, a hormone that affects energy metabolism, fertility, and bone mass, also regulates airway diameter. The finding could explain why obese people are prone to asthma.

Researchers say the results suggest that asthma associated with body weight may be relieved with medications that inhibit signaling through the parasympathetic nervous system, which mediates leptin function. The study, conducted in mice, was published in the online edition of the journal Cell Metabolism.

Obesity and anorexia

“Our study started with the clinical observation that both obesity and anorexia can lead to asthma,” says Gerard Karsenty, professor and chair of genetics and development and professor of medicine at Columbia University, and lead author of the study.

“This led us to suspect that there must be a signal coming from fat cells that somehow affects the lungs—directly or indirectly.”

The most likely candidate was leptin, a protein made by fat cells that circulates in the bloodstream and travels to the brain.

[sources]

Extensive evidence shows that obesity can cause narrowing of the airways (bronchoconstriction). When obesity develops in people with asthma, it exacerbates the breathing disorder and hampers its treatment through mechanisms that are poorly understood.

In this study, the researchers showed that abnormally low or high body weight and fat mass results in bronchoconstriction and diminished lung function. Next, they showed that leptin increases airway diameter independently of, and at a lower threshold than, its regulation of appetite.

Leptin affects the airways by decreasing the activity of the parasympathetic nervous system, a branch of the autonomic nervous system not usually associated with leptin.
The researchers also showed that regulation of airway diameter occurs regardless of local inflammation in the bronchi.

Test new therapies

The researchers conducted two subsequent experiments to determine if these findings might have bearing on asthma therapy.

In one, they took obese, asthmatic mice and administered a substance that increases lung inflammation. When they infused leptin in the brain of these mice for four days, “There was no effect on inflammation, but airway diameter and lung functions were normal,” says Karsenty.

“This showed that, at least in the mouse, you can cure obesity-related asthma without affecting inflammation.”

In the second experiment, the researchers treated obese, asthmatic mice with drugs that decrease parasympathetic tone, or rate of neuronal firing. Again, the asthma abated after several days.

“The therapeutic implication is that it may be possible to correct asthma in obese people with drugs that inhibit parasympathetic signaling—and thereby inhibit leptin deficiency-related brain signaling,” says Karsenty.

Such drugs are already available. One is tiotropium bromide, marketed under the brand name Spiriva, which is used primarily for the treatment of chronic obstructive pulmonary disease.

Clinical trials are needed before this or a more active and selective drug can be recommended for the treatment of body weight–associated asthma, Karsenty notes.

The John M. Driscoll, Jr., MD, Children’s Fund Scholars, the Irving Institute/Clinical Trials Office Pilot Award, and the National Institutes of Health supported the study.